Every 10-Q that Clorox Co Del (CLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLX filings page.
The Clorox Company reported quarterly net sales of $1.67 billion, essentially flat year over year, while nine‑month sales fell 7% to $4.77 billion as prior‑year ERP‑related shipments were lapped. Quarterly diluted EPS rose to $1.54, but nine‑month diluted EPS declined 10% to $3.47.
Gross margin compressed to 43.2% this quarter and 42.7% year‑to‑date, mainly from higher manufacturing and logistics costs and mix, partly offset by cost savings. Selling and administrative expenses and advertising both declined in dollars and as a percentage of sales, reflecting lower transformation and incentive costs.
Clorox paid $476 million to acquire Procter & Gamble’s 20% Glad venture interest and closed the roughly $2.25 billion acquisition of GOJO shortly after quarter end. To support these transactions, notes and loans payable increased to $1.59 billion, while cash and cash equivalents rose to $1.19 billion, and the company added new committed credit facilities. The long‑running ERP and digital transformation program, totaling about $580 million, was completed in the quarter.
The Clorox Company reported softer results for the quarter ended December 31, 2025. Net sales slipped to $1.67 billion, down 1% from a year ago, as lower consumption in several U.S. categories offset growth internationally. Gross profit was $722 million, with gross margin easing to 43.2% from 43.8% on higher manufacturing and logistics costs despite ongoing cost savings.
Net earnings attributable to Clorox fell to $157 million from $193 million, and diluted EPS declined 16% to $1.29, reflecting lower gross profit and lapping prior-period cyberattack insurance recoveries and tax benefits. For the first six months, net sales decreased 10% to $3.10 billion and diluted EPS dropped 18% to $1.93, pressured by lower shipments following last year’s ERP-related inventory build and the divestiture of the Better Health VMS business.
Operating cash flow remained solid at $404 million for the six-month period. Clorox plans two significant cash uses: a $476 million purchase of Procter & Gamble’s 20% interest in the Glad venture and a definitive agreement to acquire GOJO Industries for approximately $2.25 billion in cash, to be funded primarily with debt, subject to regulatory approval and customary closing conditions.
The Clorox Company (CLX) reported Q1 FY26 results with lower sales and earnings. Net sales were $1,429 million, down 19% year over year, as shipments normalized after ERP-related pull-forward in Q4 FY25. Gross profit was $596 million and gross margin declined to 41.7% from 45.8%, reflecting lower volume and higher manufacturing and logistics costs, partly offset by savings. Diluted EPS was $0.65 versus $0.80.
Operating cash flow was $93 million (vs. $221 million), driven by lower cash earnings and inventory, offset by lower receivables and higher payables. Current liabilities exceeded current assets by $539 million, primarily due to the upcoming cash purchase of P&G’s 20% Glad venture interest; the estimated fair value of that interest was $476 million, with $488 million recognized in accounts payable and accrued liabilities. Clorox cites expected operating cash flow, strong credit ratings, and available borrowing capacity to fund needs; its $1,200 million revolver was undrawn.
By segment, net sales declined: Health & Wellness $565 million (-19%), Household $362 million (-19%), Lifestyle $245 million (-23%), and International $253 million (-2%). The effective tax rate was 23.4% (vs. 41.8%). Dividends declared were $2.48 per share; share repurchases totaled $129 million.